Inducing cellular immune responses to human papillomavirus...

Details Inducing cellular immune responses to human papillomavirus... Inducing cellular immune responses to human papillomavirus...

2000-12-11

2009-08-11

Campell, Bruce (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C530S350000

Reexamination Certificate

active

07572882

ABSTRACT:
This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.

REFERENCES:
patent: 4235877 (1980-11-01), Fullerton
patent: 4487715 (1984-12-01), Nitecki et al.
patent: 4599230 (1986-07-01), Milich et al.
patent: 4837028 (1989-06-01), Allen
patent: 5013548 (1991-05-01), Haynes et al.
patent: 5128319 (1992-07-01), Arlinghaus
patent: 5180806 (1993-01-01), Dillner et al.
patent: 5200320 (1993-04-01), Sette et al.
patent: 5503829 (1996-04-01), Ladant et al.
patent: 5618536 (1997-04-01), Lowy et al.
patent: 5662907 (1997-09-01), Kubo et al.
patent: 5716620 (1998-02-01), Lowy et al.
patent: 5736142 (1998-04-01), Sette et al.
patent: 5753233 (1998-05-01), Bleul et al.
patent: 5783567 (1998-07-01), Hedley et al.
patent: 5821048 (1998-10-01), Howley et al.
patent: 5853755 (1998-12-01), Foldvari et al.
patent: 5855891 (1999-01-01), Lowy et al.
patent: 5871998 (1999-02-01), Lowy et al.
patent: 5955087 (1999-09-01), Whittle et al.
patent: 5985610 (1999-11-01), Lowy et al.
patent: 6034214 (2000-03-01), Boon et al.
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6365160 (2002-04-01), Webb et al.
patent: 6413935 (2002-07-01), Sette et al.
patent: 6419931 (2002-07-01), Vitiello et al.
patent: 6602510 (2003-08-01), Fikes et al.
patent: 2002/0098197 (2002-07-01), Sette et al.
patent: 2002/0160960 (2002-10-01), Sette et al.
patent: 2002/0168374 (2002-11-01), Kubo et al.
patent: 2002/0177694 (2002-11-01), Sette et al.
patent: 2003/0143672 (2003-07-01), Tangri et al.
patent: 2003/0216342 (2003-11-01), Fikes et al.
patent: 2003/0216343 (2003-11-01), Fikes et al.
patent: 2004/0096445 (2004-05-01), Sidney et al.
patent: 2004/0157273 (2004-08-01), Sidney et al.
patent: 2005/0049197 (2005-03-01), Sette et al.
patent: 0 044 710 (1982-01-01), None
patent: 0 226 513 (1987-06-01), None
patent: 0 433 242 (1991-06-01), None
patent: 0 378 881 (1993-06-01), None
patent: 0 429 816 (1999-06-01), None
patent: WO 91/18294 (1991-11-01), None
patent: WO 92/02543 (1992-02-01), None
patent: WO 92/12996 (1992-08-01), None
patent: WO 92/21033 (1992-11-01), None
patent: WO 93/03764 (1993-03-01), None
patent: WO 93/03764 (1993-03-01), None
patent: WO 93/22338 (1993-11-01), None
patent: WO 93/22338 (1993-11-01), None
patent: WO 94/03205 (1994-02-01), None
patent: WO 94/11738 (1994-05-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 95/07707 (1995-03-01), None
patent: WO 95/31476 (1995-11-01), None
patent: WO 96/03140 (1996-02-01), None
patent: WO 96/19496 (1996-06-01), None
patent: WO 96/22067 (1996-07-01), None
patent: WO 97/34617 (1997-09-01), None
patent: WO 97/41440 (1997-11-01), None
patent: WO 99/45954 (1999-09-01), None
patent: WO 01/00225 (2001-01-01), None
Konya et al. J Gen Virology 1997 78:2615-2620.
Ngelangel, N et al., Causes of cervical cancer in the Philippines: a case-control study J Natl Cancer Inst 1998; 90: 43-49.
NCBL #S36564.
Rotzschke, O., et al., “Peptide motifs of closely related HLA class I molecules encompass substantial differences,”Eur. J. Immunol. 22:2453-2456, VCH Verlagsgesellschaft mbH (Sep. 1992).
Rötzschke, O., and Falk, K., “Origin, structure and motifs of naturally processed MHC class II ligands,”Curr. Opin. Immunol. 6:45-51, Current Biology, Ltd. (Feb. 1994).
Rudinger, J., “Characteristics of the amino acids as components of a peptide hormone sequence,” inPeptide Hormones, Parson, J.A., ed., University Park Press, Baltimore, MD, pp. 1-7 (1976).
Castellanos, M.R., et al., “Synthetic Peptides Induce a Cytotoxic Response against Human Paillomavirus Type-18,”Gynecol. Oncol. 83:77-83, Academic Press (Jul. 2001).
Castellanos, M.R., et al., A rapid method to identify cytotoxic T-lymphocyte peptide epitopes from HLA-A2 (+) donors,Crit. Rev. Oncol. Hematol. 39:133-138, Elsevier Science Ireland, Ltd. (Jul.-Aug. 2001).
“HPV and Animal PV Nucleic Acid Sequences,”Human Papillomaviruses 1997 Compendium, Part I. HPV and Animal PV Nucleotide Sequences in GenBank style, pp. I-1-I17, The Human Papillomavirus Database (Sep. 1997).
Kast, W.M., et al., “Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins,”J. Immunol. 152:3904-3912, The American Association of Immunologist (Apr. 1994).
Ressing, M.E., et al., “Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenecity Studies of HLA-A*0201-Binding Peptides,”J. Immunol. 154:5934-5942, The American Association of Immunologists (Jun. 1995).
Rowen, D., and Lacey, C., “Toward a human papillomavirus vaccine,”Dermatologic Clinics 16:835-838, W.B. Saunders (Oct. 1998).
Yoon, H., et al., “Synthetic peptides of human papillomavirus type 185 E6 harboring HLA-A2.1 motif can induce peptide-specific cytotoxic T-cells from peripheral blood mononuclear cells of healthy donors,”Virus Res. 54:23-29, Elsevier Science B.V. (Mar. 1998).
Co-pending U.S. Appl. No. 08/205,713, inventor Grey, filed Mar. 4, 1994 (Not Published).
Co-pending U.S. Appl. No. 08/344,824, inventors Sette et al., filed Nov. 23, 1994 (Not Published).
Co-pending U.S. Appl. No. 08/347,610, inventors Kubo et al., filed Dec. 1, 1994 (Not Published).
Co-pending U.S. Appl. No. 09/017,524, inventors Kubo et al., filed Feb. 3, 1998 (Not Published).
Co-pending U.S. Appl. No. 09/641,528, inventors Sette et al., filed Aug. 15, 2000 (Not Published).
Alexander, M., et al., “Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope,”Am. J. Obstet. Gynecol. 175:1586-1593, Mosby-Year Book (1996).
Bremers, A.J.A., et al., “The Use of Epstein-Barr Virus-Transformed B Lymphocyte Cell Lines in a Peptide-Reconstitution Assay: Identification of CEA-Related HLA-A*0301-Restricted Potential Cytotoxic T-Lymphocyte Epitopes,”J. Immunother. 18:77-85, Lippincott-Raven (1995).
Busch, R., et al., “Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces,”Int. Immunol. 2:443-451, Oxford University Press (1990).
Feltkamp, M.C.W., et al., “Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells,”Eur. J. Immunol. 23:2242-2249, VCH Verlagsgesellschaft (1993).
Kast, W.M., et al., “Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins,”J. Immunol. 152:3904-3912, American Association of Immunologists (1994).
Melief, C.J.M., and Kast, W.M., “Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication in General,”Cancer Surv. 13:81-99, Cold Spring Harbor Press (1992).
Rammensee, H-G., et al., “MHC ligands and peptide motifs: first listing,”Immunogen. 41:178-228, Springer-Verlag (1995).
Ressing, M.E., et al., “Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A*0201-Binding Peptides,”J. Immunol. 154:5934-5943, American Association of Immunologists (1995).
Schultz, M., et al., “Peptide-induced antiviral protection by cytotoxic T cells,”Proc. Natl. Acad. Sci. USA 88:991-993, National Academy of Sciences (1991).
Sidney, J., et al., “Specificity and Degeneracy in Peptide Binding to HLA-B7-Like Class I Molecules,”J. Immunol. 157:3480-3490, American Association of Immunologists (1996).
Toes, R.E.M., et al., “Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses e

Affiliated with

Also associated with

Rating

Inducing cellular immune responses to human papillomavirus... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inducing cellular immune responses to human papillomavirus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inducing cellular immune responses to human papillomavirus... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4077951